Conventional supportive and possible future therapy in patients affected by GITS.
Hodler
J
J
University of Bern, Switzerland.
Cottier
H
H
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003422:Critical Care; D016207:Cytokines / Q000502:physiology; D004731:Endotoxins / Q000009:adverse effects; D004750:Enteral Nutrition; D005440:Fluid Therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D007422:Intestines / Q000382:microbiology*; D008222:Lymphokines / Q000502:physiology; D009102:Multiple Organ Failure / Q000209:etiology / Q000517:prevention & control; D012772:Shock, Septic / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002316:Cardiotonic Agents; D016207:Cytokines; D004731:Endotoxins; D007155:Immunologic Factors; D008222:Lymphokines; D014665:Vasodilator Agents